MedTrace Logo

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

NCT04163783 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-11-15

No results posted yet for this study

Summary

Phase 1 study in healthy subjects to determine the effect of an 8-hour fast from food on the pharmacokinetics of \[14C\]-BGB-3111.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C]-BGB-3111

20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,

DRUG

BGB-3111

Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • William Novotony, MD · BeiGene

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-29
Primary Completion
2017-04-18
Completion
2017-04-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04163783 on ClinicalTrials.gov